Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484222 | 0.91 | DRD2 (0.38) | GRIN1GRIN2BP2RX7KMT2A | |
| SCHEMBL1482892 | 0.90 | KMT2A (0.45) | GRIN1GRIN2BCCR2P2RX7KMT2A | |
| SCHEMBL1482685 | 0.88 | KMT2A (0.48) | BRD4KMT2A | |
| SCHEMBL1482808 | 0.87 | CCR2 (0.49) | GRIN1GRIN2BCCR2MRGPRX4BRD4 | |
| SCHEMBL1484274 | 0.86 | CCR2 (0.42) | GRIN1GRIN2BCCR2MRGPRX4KMT2A | |
| SCHEMBL1482474 | 0.86 | CNR1 (0.39) | P2RX7KMT2A | |
| SCHEMBL1482680 | 0.86 | MDM2 (0.39) | GRIN1GRIN2BKMT2AMEN1 | |
| SCHEMBL1483030 | 0.82 | DRD2 (0.47) | CCR2MRGPRX4 | |
| SCHEMBL1482982 | 0.78 | KDM4E (0.51) | KMT2AMEN1 | |
| SCHEMBL1483164 | 0.78 | DHFR (0.44) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | GRIN1 2990/4885GRIN2B 2072/4885CCR2 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.